Regeneron Pharmaceuticals faces valuation scrutiny after FDA approval for EYLEA HD dosing. Despite a 34% annual return, YTD performance is negative. Analysis indicates modest undervaluation at $763.04, with a fair value of $873.78, despite a high P/E ratio.

NodeGuardian

2026-04-17 06:31:37

Abstract generation in progress

Regeneron Pharmaceuticals (REGN) is under valuation scrutiny after the FDA approved extended dosing for EYLEA HD, easing treatment schedules. Despite a 34% one-year total shareholder return, the stock’s year-to-date performance is slightly negative. Simply Wall St’s analysis suggests REGN is modestly undervalued at $763.04, with a fair value pegged at $873.78, though its P/E ratio is higher than the US Biotech average.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

Reward
like
Comment
Repost
Share

Comment

Add a comment

No comments

Trending Topics
View More
#
GatePreIPOsLaunchesWithSpaceX
187.47K Popularity
#
Gate13thAnniversaryLive
739.11K Popularity
#
AltcoinsRallyStrong
7.31M Popularity
#
AnthropicvsOpenAIHeatsUp
1.06M Popularity
#
KalshiFacesNevadaRegulatoryClash
458.44K Popularity

Sitemap

Assessing Regeneron Pharmaceuticals (REGN) Valuation After FDA Approval Extends EYLEA HD Dosing Intervals

Trending Topics

GatePreIPOsLaunchesWithSpaceX

Gate13thAnniversaryLive

AltcoinsRallyStrong

AnthropicvsOpenAIHeatsUp

KalshiFacesNevadaRegulatoryClash

Pin